SCHEMBL3255149

SCHEMBL3255149

CC1(c2ccccc2)NC(COc2cccc(F)c2)(OC(=O)C(F)(F)F)NC1c1ccccc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.33
CCR2 P41597 1/20 0.33
ADAM17 P78536 1/20 0.33
P2RX7 Q99572 2/20 0.32
MRGPRX4 Q96LA9 1/20 0.31
PPARG P37231 1/20 0.31
PPARA Q07869 1/20 0.31
SSTR4 P31391 1/20 0.31
HCRTR2 O43614 2/20 0.31
HCRTR1 O43613 1/20 0.31
NR4A2 P43354 1/20 0.31
PKM P14618 1/20 0.31
LMNA P02545 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
MAOB P27338 1/20 0.30
AURKA O14965 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3257059 0.92 AURKA (0.35) HCRTR2HCRTR1AURKA
SCHEMBL3259017 0.90 ALDH1A1 (0.34) MEN1ALDH1A1HPGDKMT2AMRGPRX4
SCHEMBL3256735 0.83 RORC (0.33) AURKA
SCHEMBL3248388 0.81 ALDH1A1 (0.38) MEN1ALDH1A1HPGDKMT2AP2RX7
SCHEMBL3254116 0.81 RORC (0.33)
SCHEMBL3253716 0.81 TRPA1 (0.32) ALDH1A1
SCHEMBL3255027 0.80 AURKA (0.35) AURKA
SCHEMBL3251075 0.80 TP53 (0.35) ALDH1A1HPGDKMT2AAURKA
SCHEMBL3256116 0.79 RORC (0.31)
SCHEMBL3258655 0.78 ADRA1D (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741493-B2 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives; antiinflammatory agent, neurodegenerative diseases; inflammatory bowel disease, rheumatoid arthritis and diseases associated with central nervous system, such as Alzheimer's disease AVENTIS PHARMACEUTICALS INC. (US) 2010-06-22 US disclosed
EP-1651613-B1 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS AVENTIS PHARMA INC (US) 2010-05-26 EP disclosed
US-20080132550-A1 HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS AVENTIS PHARMACEUTICALS INC. (US) 2008-06-05 US disclosed
US-7326792-B2 Heterocyclic compounds as P2X7 ion channel blockers AVENTIS PHARMACEUTICALS INC. (US) 2008-02-05 US disclosed
EP-1651613-A1 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS Aventis Pharmaceuticals, Inc. (US) 2006-05-03 EP disclosed
WO-2005014555-A1 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS AVENTIS PHARMACEUTICALS INC. (US) 2005-02-17 WO disclosed
US-20050026916-A1 Heterocyclic compounds as P2X7 ion channel blockers AVENTIS PHARMACEUTICALS INC. (US) 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132550-A1 HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS P2RX3, P2RX2, P2RX5 MEN1 3313/4885ALDH1A1 1913/4885HPGD 1294/4885
US-20050026916-A1 Heterocyclic compounds as P2X7 ion channel blockers P2RX3, P2RX2, P2RX5 MEN1 3313/4885ALDH1A1 1913/4885HPGD 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.